There is a lot of movement in prostate cancer screening research and practice these days, as this week’s JAMA illustrates:
🔵 15-year update to CAP trial
🔵 Preliminary communication from ProScreen
🔵 Insightful editorial by Jeff Tosoian, MD, MPH and colleagues

1/n

Awesome work by Allison May, MD on the transition from clear cell to sarcomatoid RCC! Much deserved winner at the early career showcase. You really haven’t lived until you’ve seen spatial transcriptomics figures. #AUA24 #AUA2024

A new urine test that measures 18 genes associated with #prostatecancer provides higher accuracy for detecting clinically significant cancers than PSA & other biomarker tests, according to a recent JAMA Oncology study.

Jeff Tosoian, MD, MPH is first author of the study.

spr.ly/6010bQP5A

For those that prefer watching to reading (i.e. everyone). Thanks for having me on! UroToday.com Andrea Miyahira